Cargando…
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
BACKGROUND: Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. METHODS: REDUCE-IT (The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial), a multicenter, double-blind, placebo-controlled...
Autores principales: | Peterson, Benjamin E., Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Gibson, C. Michael, Pinto, Duane, Giugliano, Robert P., Budoff, Matthew J., Tardif, Jean-Claude, Verma, Subodh, Ballantyne, Christie M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752247/ https://www.ncbi.nlm.nih.gov/pubmed/33148016 http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050276 |
Ejemplares similares
-
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
por: Peterson, Benjamin E., et al.
Publicado: (2022) -
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022) -
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT
por: Selvaraj, Senthil, et al.
Publicado: (2022) -
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
por: Majithia, Arjun, et al.
Publicado: (2021) -
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
por: Olshansky, Brian, et al.
Publicado: (2023)